FDA Clearance Tracker · P990004-S067
SURGIFLO® Hemostatic Matrix, SURGIFLO® Hemostatic Matrix Kit with Thrombin
Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Dec 30, 2024
Approved
Time to decision
241 days
Received May 3, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990004-S067
- Device name
- SURGIFLO® Hemostatic Matrix, SURGIFLO® Hemostatic Matrix Kit with Thrombin
- Applicant
- Ferrosan Meidcal Devices A/S
- Applicant location
- Soeborg
- Received
- May 3, 2024
- Decided
- Dec 30, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P990004
Device type
- Device class
- Class III
- Regulation
- 21 CFR 878.4490
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
Approval for a change to the syringe plunger stopper
Source documents
Other decisions for Ferrosan Meidcal Devices A/S
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.